Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tong Yang
Observed name:
Yang Tong
Institution:
First Hospital of Jilin University
Observed institutions:
Sichuan University,
West China Medical Center of Sichuan University,
West China Second University Hospital of Sichuan University,
West China Hospital of Sichuan University,
First Hospital of Jilin University
ORCID:
0009-0004-6780-7965
Observed ORCID:
0009-0004-6780-7965
OpenAlex ID:
A5100815602
FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2024
·
Qingsong Guo
, Bei Gao
, et al.
·
Molecular Cancer Therapeutics
·
25
PDF
Adoptive Infusion of Tolerogenic Dendritic Cells Prolongs the Survival of Pancreatic Islet Allografts: A Systematic Review of 13 Mouse and Rat Studies
2012
·
Guixiang Sun
, Juan Shan
, et al.
·
PLoS ONE
·
22
Adoptive transfusion of tolerance dendritic cells prolongs the survival of cardiac allograft: a systematic review of 44 basic studies in mice
2012
·
Wenqiao Wu
, Juan Shan
, et al.
·
Journal of Evidence-Based Medicine
·
18
Adoptive infusion of tolerance dendritic cells prolongs survival of small intestine allografts in rats: systematic review and meta‐analysis
2013
·
Guixiang Sun
, Juan Shan
, et al.
·
Journal of Evidence-Based Medicine
·
6
Adoptive transfusion of tolerance dendritic cells prolongs the survival of skin allografts in mice: a systematic review
2013
·
Yanni Zhou
, Juan Shan
, et al.
·
Journal of Evidence-Based Medicine
·
6
Ambient aromatic hydrocarbons and prostate cancer: mechanistic evidence linking benzene and PAH exposure to tumor progression
2026
·
Hao Wu
, Hongliang Cao
, et al.
·
Frontiers in Cell and Developmental Biology
·
1
PDF
Figure S1 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2026
·
Qingsong Guo
, Bei Gao
, et al.
Figure S2 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2026
·
Qingsong Guo
, Bei Gao
, et al.
Table. S4 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2026
·
Qingsong Guo
, Bei Gao
, et al.
Figure S5 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2026
·
Qingsong Guo
, Bei Gao
, et al.
Table. S3 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2026
·
Qingsong Guo
, Bei Gao
, et al.
Figure S6 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2026
·
Qingsong Guo
, Bei Gao
, et al.
Figure S3 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2026
·
Qingsong Guo
, Bei Gao
, et al.
Table.S1 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2026
·
Qingsong Guo
, Bei Gao
, et al.
Table S2 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2026
·
Qingsong Guo
, Bei Gao
, et al.
Figure S4 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2026
·
Qingsong Guo
, Bei Gao
, et al.
Hypertensive disorders of pregnancy increase neonatal cerebral regional tissue oxygen saturation in the early postnatal period: partial mediation by preterm birth
2025
·
Yao Zhang
, Tong Yang
, et al.
·
Frontiers in Cell and Developmental Biology
PDF
Data from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2024
·
Qingsong Guo
, Bei Gao
, et al.
Figure S1 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2024
·
Qingsong Guo
, Bei Gao
, et al.
Table. S4 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2024
·
Qingsong Guo
, Bei Gao
, et al.
Table S2 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2024
·
Qingsong Guo
, Bei Gao
, et al.
Table.S1 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2024
·
Qingsong Guo
, Bei Gao
, et al.
Figure S5 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2024
·
Qingsong Guo
, Bei Gao
, et al.
Figure S2 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2024
·
Qingsong Guo
, Bei Gao
, et al.
Figure S3 from FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
2024
·
Qingsong Guo
, Bei Gao
, et al.
Show more works
View as search
Works count:
29
Citation count:
78
H-index:
5
I10-index:
3
Year
Topic
Type